

# CEDARLANE®

Part of TCP Analytical Group

## LYMPHOLYTE® CELL SEPARATION MEDIA



CEDARLANE® is an ISO 9001:2015 and  
ISO 13485:2016 registered company


# LYMPHOLYTE®

CEDARLANE's Lympholyte® Cell Separation density gradient centrifugation media has been specifically designed for the isolation of viable lymphocytes from mouse, rat, rabbit, human and other mammalian cell populations. The resulting cell population demonstrates a high, nonselective recovery of viable lymphocytes that are suitable for use as target cells in cytotoxicity and FACS assays and in in vivo / in vitro functional studies. All products are supplied in liquid format with varying densities.

## Applications for Lympholyte® include:

- Isolation of viable lymphocytes from lymphoid organs by removal of red and dead cells.
- Removal of dead cells and debris:
  - From lymphocyte suspensions after treatment with antibody plus complement or following cell culture.
  - Following sequential cytotoxicity studies eg. B-cell depletion.
  - From various clonal and hybridoma cell lines.
- Removal of erythrocytes, dead cells and debris From various clonal and hybridoma cell lines. (Lympholyte®-M and Lympholyte®-R)
- Isolation of murine nuclear epidermal cells. (Lympholyte®-M)
- Isolation of mononuclear cells from bone marrow preparations. (Lympholyte®-H)

## Lympholyte® Cell Separation Procedure



**A:** Gently layer the cell suspension or whole blood over top of the Lympholyte® making sure not to mix the two layers.

**B:** Alternatively, slowly add Lympholyte® to a Pasteur pipette allowing gravity to layer it under the whole blood or cell suspension.

**C:** Centrifuge the tube at room temperature for indicated time at the indicated speed.

**D:** Carefully remove the cells at the interface using a Pasteur pipette and transfer into a new centrifuge tube for washing.

## LYMPHOLYTE® CELL SEPARATION MEDIA

Product	Density	Size	Main Application	Cat. #
Lympholyte®-H Cell Separation Media	1.0770 ± 0.001 @ 25°C, g/ml	5x30 mL	Isolation of viable <b>HUMAN</b> lymphocytes from peripheral blood	CL5010 CL5010-R
	1.0770 ± 0.001 @ 25°C, g/ml	100 mL	Isolation of viable <b>HUMAN</b> lymphocytes from peripheral blood	CL5015 CL5015-R
	1.0770 ± 0.001 @ 25°C, g/ml	6x100 mL	Isolation of viable <b>HUMAN</b> lymphocytes from peripheral blood	CL5016 CL5016-R
	1.0770 ± 0.001 @ 25°C, g/ml	500 mL	Isolation of viable <b>HUMAN</b> lymphocytes from peripheral blood	CL5020 CL5020-R
	1.0770 ± 0.001 @ 25°C, g/ml	6x500 mL	Isolation of viable <b>HUMAN</b> lymphocytes from peripheral blood	CL5026 CL5026-R
Lympholyte®-M Cell Separation Media	1.0875 ± 0.001 @ 25°C, g/ml	5x30 mL	Isolation of viable <b>MOUSE</b> lymphocytes from lymphoid tissue	CL5030
	1.0875 ± 0.001 @ 25°C, g/ml	100 mL	Isolation of viable <b>MOUSE</b> lymphocytes from lymphoid tissue	CL5031
	1.0875 ± 0.001 @ 25°C, g/ml	500 mL	Isolation of viable <b>MOUSE</b> lymphocytes from lymphoid tissue	CL5035
Lympholyte®-Mammal Cell Separation Media  <i>For species tested please contact tech@cedarlanelabs.com</i>	1.0860 ± 0.001 @ 25°C, g/ml	5x30 mL	Isolation of viable lymphocytes from peripheral blood of most <b>mammalian</b> species	CL5110
	1.0860 ± 0.001 @ 25°C, g/ml	100 mL	Isolation of viable lymphocytes from peripheral blood of most <b>mammalian</b> species	CL5151
	1.0860 ± 0.001 @ 25°C, g/ml	500 mL	Isolation of viable lymphocytes from peripheral blood of most <b>mammalian</b> species	CL5120
Lympholyte®-Rabbit Cell Separation Media	1.0965 ± 0.001 @ 25°C, g/ml	5x30 mL	Isolation of viable <b>RABBIT</b> lymphocytes from lymphoid tissue	CL5050
Lympholyte®-R Cell Separation Media	1.0940 ± 0.001 @ 25°C, g/ml	5x30 mL	Isolation of viable <b>RAT</b> lymphocytes from lymphoid tissue	CL5040
	1.0940 ± 0.001 @ 25°C, g/ml	100 mL	Isolation of viable <b>RAT</b> lymphocytes from lymphoid tissue	CL5041
	1.0940 ± 0.001 @ 25°C, g/ml	500 mL	Isolation of viable <b>RAT</b> lymphocytes from lymphoid tissue	CL5045
Lympholyte®-poly Cell Separation Media	1.113 ± 0.001 @ 25°C, g/ml	100 mL	Isolation of viable <b>HUMAN</b> polymorphonuclear cells	CL5070
	1.113 ± 0.001 @ 25°C, g/ml	250 mL	Isolation of viable <b>HUMAN</b> polymorphonuclear cells	CL5071
Lympholyte®-1.1	1.100 ± 0.001 @ 25°C, g/ml	500 mL	A high density Lympholyte® solution which can be diluted with PBS (withough Ca <sup>2+</sup> /Mg <sup>2+</sup> ). Isolation of pancreatic islet cells prior to expanding them in vitro	CL6255

FOR MORE INFORMATION  
VISIT OUR WEBSITE

[WWW.CEDARLANELABS.COM/CUSTOM](http://WWW.CEDARLANELABS.COM/CUSTOM)

# LYMPHOLYTE® CELL SEPARATION MEDIA REFERENCES

## Lympholyte®-M

Sun Y, et al. (2023) Targeting TBK1 to overcome resistance to cancer immunotherapy. *Nature*. 615(7950):158-167

Wang CJ, et al. (2022) Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity. *Nat Commun*. 13(1):6757.

van de Ven K, et al. (2022) A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. *Sci Adv*. 8(50):eadc9937.

## Lympholyte®-Mammal

Ye D, et al. (2024) RAGE in circulating immune cells is fundamental for hippocampal inflammation and cognitive decline in a mouse model of latent chronic inflammation. *Brain Behav Immun*. 116:329-348.

Gorman J, et al. (2024) Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. *Nat Commun*. 15(1):285.

Rotolo A, et al. (2023) Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients. *Cell Rep Med*. 4(10):101241.

## Lympholyte®-Rabbit

Lassaunière R, et al. (2023) Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine. *Vaccine*. 41(43):6505-6513.

Takeuchi Y, et al. (2017) Ulcer healing effect of autologous mixed sheets consisting of fibroblasts and peripheral blood mononuclear cells in rabbit ischemic hind limb. *Am J Transl Res*. 9(5):2340-2351.

## Lympholyte®-R

Walker VE, et al. (2020) Analysis of DNA Adducts and Mutagenic Potency and Specificity in Rats Exposed to Acrylonitrile. *Chem Res Toxicol*. 33(7):1609-1622.

Rabani R, et al. (2018) Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis. *Eur Respir J*. 51(4):1702021.

## Lympholyte®-H

Sardina F, et al. (2023) New cellular imaging-based method to distinguish the SPG4 subtype of hereditary spastic paraplegia. *Eur J Neurol*. 30(6):1734-1744.

Capitani N, et al. (2022) A COVID-associated variant in the ciliogenesis protein CCDC28B disrupts immune synapse assembly. *Cell Death Differ*. 29(1):65-81.

Evgin L, et al. (2022) Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. *Sci Transl Med*. 14(640):eabn2231.

Liu YC, et al. (2022) Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. *N Engl J Med*. 386(21):1998-2010.

Ye C, et al. (2022) Single-cell and spatial transcriptomics reveal the fibrosis-related immune landscape of biliary atresia. *Clin Transl Med*. 12(11):e1070.

## Lympholyte®-1.1

Kim YK, et al. (2022) Zinc transporter 8 haploinsufficiency protects against beta cell dysfunction in type 1 diabetes by increasing mitochondrial respiration. *Mol Metab*. 66:101632.

Jamison BL, et al. (2022) Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the NOD Mouse. *Diabetes*. 71(3):483-496.

# CEDARLANE®

Part of TCP Analytical Group

 CANADA

4410 Paletta Ct Suite A - L7L 5R2  
Burlington, Ontario, Canada  
E-mail: [general@cedarlanelabs.com](mailto:general@cedarlanelabs.com)  
Toll Free: 1-800-268-5058  
Ph: (289) 288-0001  
Fax: (289) 288-0020

 USA

1210 Turrentine St, Burlington, North  
Carolina - 27215, United States  
E-mail: [service@cedarlanelabs.com](mailto:service@cedarlanelabs.com)  
Toll Free: 1-800-721-1644  
Ph: (336) 513-5135  
Fax: (336) 513-5138



CEDARLANE® is an ISO 9001:2015 and  
ISO 13485:2016 registered company